-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on BioCryst Pharma, Lowers Price Target to $13

Benzinga·08/06/2026 17:07:43
Listen to the news
RBC Capital analyst Brian Abrahams maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers the price target from $14 to $13.